Abstract
Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States (353)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
